NA

Nature's Sunshine Products, Inc.

NATRConsumer DefensiveNASDAQ

Packaged Foods · Last scanned Jul 18, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$480.1M
+5.7% YoY
Net Income
$19.5M
+153.7% YoY
EBITDA
$43.8M
+33.4% YoY
Free Cash Flow
$23.2M

Scan Results

Daily timeframe
1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 8CONFIRMED Below MA2000.3% below MA200
RSI OverboughtRSI 78.0, above 70, stock may be overbought
Jul 7 Below MA2000.6% below MA200
About Nature's Sunshine Products, Inc.

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and. At a $359.3M market cap, Nature's Sunshine Products, Inc. ranks as a small-cap company within consumer defensive. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.

Key stats
Market Cap$359.3M
P/E (TTM)18.57
Fwd P/E15.96
EPS$1.10
Beta0.87
52W Change+37.4%
ROE12.4%
Analysis

With $87.6M in cash and $22.4M in debt, NATR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $23.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 12.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $421.9M to $480.1M.

With cash comfortably exceeding debt, NATR has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NATR.

Links
More Consumer Defensive stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms